UNITAID and Clinton Foundation Announce HIV Med Price Cuts
The combined efforts of the William J. Clinton Foundation HIV/AIDS Initiative and UN-supported drug funding initiative UNITAID have enabled generic medicine manufacturers to lower the prices of their second-line antiretroviral medications, Agence France-Presse (AFP) reports (afp.google.com, 4/28).
The price cut would be as high as 19 percent for second-line treatments—including tenofovir, lamivudine and lopinavir/ritonavir—which are essential for patients who have developed resistance to first-line drugs. In addition to lowering the prices of these generics, UNITAID announced six new and affordable child-friendly formulations, made available through its pediatric project.
“Today’s announcement is an important step in helping to save the millions of children and adults infected with HIV in the developing world who still lack access to life-saving drugs,” President Bill Clinton told AFP yesterday.
According to the article, roughly 500,000 people will need second-line treatment by 2010.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Beth Benne, RN, is HIV negative, but
the virus has impacted her life. She currently supervises a biannual HIV/AIDS awareness week as
the director of the student health center at Pierce College, a
community commuter school in Woodland Hills, California.
Woman of the Month is supported by exclusive advertising from Gilead.
Overheard in the Women's Forum
"I think that it's OK to be angry. I am sometimes—it's natural—we are HIV positive. but I always try to not let myself stay there too long. Let yourself feel you are human. You should not beat yourself up about being angry."
